IL16 and colorectal carcinoma: The results showed that MLN8237 effectively inhibited Aurora-A activation (Fig. 5A), and both IL-16 mRNA and protein expression were upregulated in MLN8237-treated human and mouse CRC cells (Fig. 5B–G).